Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | DGKZ | Q13574 | 4/20 | 0.33 |
| ▸ | DGKA | P23743 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26925963 | 0.99 | SIGMAR1 (0.45) | SIGMAR1HRH3DGKZDGKADPP8 | |
| SCHEMBL26944549 | 0.91 | SIGMAR1 (0.40) | SIGMAR1HRH3DGKZDGKA | |
| Hydrochloric Acid SCHEMBL26925943 | 0.89 | SIGMAR1 (0.39) | SIGMAR1HRH3DGKZDGKA | |
| SCHEMBL21910451 | 0.88 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8ACHE | |
| SCHEMBL21910774 | 0.88 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8ACHE | |
| SCHEMBL21910443 | 0.88 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8ACHE | |
| SCHEMBL29922860 | 0.88 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8ACHE | |
| Hydrochloric Acid SCHEMBL21831114 | 0.86 | SIGMAR1 (0.44) | SIGMAR1HRH3DPP8 | |
| Hydrochloric Acid SCHEMBL21830987 | 0.86 | SIGMAR1 (0.44) | SIGMAR1HRH3DPP8 | |
| SCHEMBL26946002 | 0.86 | SIGMAR1 (0.36) | SIGMAR1HRH3DGKZDGKADPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | SIGMAR1 4195/4885HRH3 3562/4885DGKZ 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.